Remikiren

This classification denotes a protease inhibitor and antihypertensive agent with the molecular formula C33H50N4O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LC7FBL96A4, chemically known as 1h-imidazole-4-propanamide, n-(1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((2-(((1,1-dimethylethyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (1s-(1r*(r*(r*)),2s*,3r*))- but generally known as remikiren, which bears US NIH Compound Identifier 5462340. European Medicines Agency schedules Remikiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10273MIG. The term REMIKIREN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules remikiren in its Anatomical Therapeutic Chemical (ATC) Classification. REMIKIREN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule remikiren under HS 29332990 and SITC 51573. As of Q4 2014, REMIKIREN remains the US FDA Preferred Term for this commodity. Remikiren bears US NLM identifiers UMLS ID C0209499 and NCI Concept Code C73099. SMILES: S(=O)(=O)(CC(C(=O)NC(C(=O)NC(C(O)C(O)C1CC1)CC1CCCCC1)Cc1[nH]cnc1)Cc1ccccc1)C(C)(C)C.